drugset
drugset / Trial / NCT00117351

VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features

NCT00117351 ↗

Phase 2 Terminated Millennium Pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of VELCADE in patients with previously treated stage IIIB and IV bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features.

Timeline

Start
2005-04
Primary completion
2007-06
Completion
2007-07

Outcome

Outcome not reported

Stopped: “insufficient efficacy”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule — —

Indications

lung adenocarcinoma